Alternative Signaling Pathways as Potential Therapeutic Targets for Overcoming EGFR and c-Met Inhibitor Resistance in Non-Small Cell Lung Cancer

The use of tyrosine kinase inhibitors (TKIs) against EGFR/c-Met in non-small cell lung cancer (NSCLC) has been shown to be effective in increasing patient progression free survival (PFS), but their efficacy is limited due to the development of resistance and tumor recurrence. Therefore, understandin...

Descripción completa

Detalles Bibliográficos
Autores principales: Fong, Jason T., Jacobs, Ryan J., Moravec, David N., Uppada, Srijayaprakash B., Botting, Gregory M., Nlend, Marie, Puri, Neelu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817236/
https://www.ncbi.nlm.nih.gov/pubmed/24223799
http://dx.doi.org/10.1371/journal.pone.0078398

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3817236/
https://www.ncbi.nlm.nih.gov/pubmed/24223799
http://dx.doi.org/10.1371/journal.pone.0078398

Ejemplares similares